While many migraine sufferers experience traditional symptoms such as nausea or sensitivity to light and sound, migraine attacks can also involve symptoms like neck pain or sinus pain that are not traditionally associated with migraine headaches.
New data show that significantly more patients using the investigational migraine treatment Trexima early in their migraine attacks were pain free at two hours and experienced relief from both traditional and non-traditional symptoms, compared to patients taking placebo. These data were presented today at the 59th Annual Meeting of the American Academy of Neurology.
In these studies, more than 1,100 patients treated more than 3,300 migraine attacks. At the beginning of the studies, many patients experienced traditional migraine symptoms: nausea (27-33 percent), sensitivity to light (69-74 percent) and sensitivity to sound (62-69 percent). Additionally, many patients also reported the non-traditional migraine-associated symptoms of sinus pain/pressure (39-44 percent) or neck pain/discomfort (59-61 percent).
?One of the challenges in migraine treatment is helping patients get relief for the specific symptoms associated with each attack,? said Robert Kaniecki, MD, director of the Headache Center at the University of Pittsburgh. ?These data are important because for the first time we have evidence of efficacy in treating both traditional and non-traditional migraine-associated symptoms across multiple migraine attacks.?
Trexima, the proposed brand name for a single tablet containing sumatriptan 85 mg formulated with RT Technology ? and naproxen sodium 500 mg, is currently under review by the US Food and Drug Administration for the acute treatment of migraines in adults.